In this study, we sought to investigate the effects of G-CSF exposure on CRS, ICANS, hematologic toxicities and infections after CAR T. For the primary analysis, we interrogated the outcomes of 197 lymphoma patients treated at our centers with commercial anti-CD19 CAR T cells. The gene discussed is CSF3; the disease is lymphoma.